title: Radiation therapy for orbital lymphoma.
abstract: OBJECTIVE
  To describe radiation techniques and evaluate outcomes for orbital lymphoma.
  
  
  METHODS
  Forty-six patients (and 62 eyes) with orbital lymphoma treated with radiotherapy between 1987 and 2003 were included. The majority had mucosa-associated lymphoid tissue (48%) or follicular (30%) lymphoma. Seventeen patients had prior lymphoma at other sites, and 29 had primary orbital lymphoma. Median follow-up was 46 months.
  
  
  RESULTS
  The median dose was 30.6 Gy; one-third received <30 Gy. Electrons were used in 9 eyes with disease confined to the conjunctiva or eyelid, and photons in 53 eyes with involvement of intraorbital tissues to cover entire orbit. Local control rate was 98% for all patients and 100% for those with indolent lymphoma. Three of the 26 patients with localized primary lymphoma failed distantly, resulting in a 5-year freedom-from-distant-relapse rate of 89%. The 5-year disease-specific and overall survival rates were 95% and 88%, respectively. Late toxicity was mainly cataract formation in patients who received radiation without lens block.
  
  
  CONCLUSIONS
  A dose of 30 Gy is sufficient for indolent orbital lymphoma. Distant relapse rate in patients with localized orbital lymphoma was lower than that reported for low-grade lymphoma presenting in other sites. Orbital radiotherapy can be used for salvage of recurrent indolent lymphoma.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. pzhou@partners.org
authors.forename: Ping
authors.initials: P
authors.lastname: Zhou
authors.forename: Andrea K
authors.initials: AK
authors.lastname: Ng
authors.forename: Barbara
authors.initials: B
authors.lastname: Silver
authors.forename: Sigui
authors.initials: S
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Hua
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002386:Cataract / Q000209:etiology; D003315:Cornea / Q000528:radiation effects; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D012008:Recurrence